Majority of Voters Support Drug Price Reforms
A recent survey indicates substantial backing for Trump’s “most preferred country” policy, along with expectations that lawmakers will tackle high pharmaceutical prices. The Drug Reform Alliance commissioned the survey, which was executed by National Research Inc.
The findings reveal that 85% of voters acknowledge that the prices of prescription drugs are excessively high, with nearly the same number attributing these costs predominantly to pharmaceutical companies.
Voter preferences show that 86% are more inclined to support candidates advocating for drug cost reductions, while 78% would be less likely to back those who accept contributions from the pharmaceutical industry.
A noteworthy 90% of respondents concurred with the notion that “Congressional candidates need to stop large political donations from major pharmaceutical companies due to potential conflicts of interest.”
During the 2024 election cycle, the Political Action Committee focused on Pharmaceutical and Health Products has contributed upwards of $16 million to various campaigns.
“Americans are making their voices heard, and Congress should take note. It’s time for President Trump to lower prescription drug prices. Across the nation, people are struggling with high costs, and they feel that Big Pharma prioritizes profits over people,” a representative stated.
With the 2026 election gaining momentum, the message is clear: action is needed. Voter attention is keen.
The survey also pointed out Trump’s executive order aimed at achieving “most preferred nations” pricing for drugs. This order tasks the Department of Commerce and U.S. Trade Representative Jamieson Greer with addressing “irrational and discriminatory” foreign policies affecting drug pricing.
Furthermore, Health and Human Services Director Robert F. Kennedy Jr. will outline specific targets for prescription drug pricing within a month, as mandated.
When queried about the “most preferred country” policy, 78% expressed support, including 61% of Democrats, 77% of independents, and a solid 96% of Republicans.
Among Republican respondents, Trump was the preferred choice over Kennedy and his “American Health Again” initiative. He garnered 46% support, while Kennedy received 14%, and a mere 2% opted for Congress.
Another proposal gaining traction involved limiting prescription drug advertisements for consumers, with 78% agreeing that it’s a conflict of interest for news organizations to air healthcare-related ads.
The survey took place from May 28 to June 1, involving 1,000 registered voters. The results come with a margin of error of ±3.1 percentage points and a confidence interval of 95%. The breakdown of participants included 35% Republicans, 33% Democrats, and 32% independents.
